Immune system plays a major role in brain damage after repeated concussions, study suggests

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
Seeking Alpha

Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
News Medical

Targeting complement with an inhibitor may prevent preterm birth and protect the baby’s brain

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
Nature

FDA approves first complement factor D inhibitor

The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
EurekAlert!

A surprising suspect behind concussion trouble: Your own immune system

Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...
Seeking Alpha

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. (ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its ...
The American Journal of Managed Care

Efficacy and Safety Trials Results of Complement Inhibitors

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...
Business Wire

Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
The American Journal of Managed Care

Complement Inhibitors may be Ineffective for Reducing Omicron Infection Severity

A single-center study suggests complement inhibitors do not reduce the severity of a COVID-19 Omicron infection in patients with paroxysmal nocturnal hemoglobinuria (PNH). A COVID-19 infection can ...
EurekAlert!

Scientists take aim at a novel target to reduce preterm birth

The Medical University of South Carolina research team who conducted the study published in Cells included (front to back) Dr. Eliza McElwee, Dr. Stephen Tomlinson and Devin Hatchell. A research team ...
Business Wire

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...